BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 2010;3:369-78. [PMID: 21179597 DOI: 10.1177/1756285610388343] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol 2013;170:1293-307. [PMID: 23425327 DOI: 10.1111/bph.12129] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
2 Blumenfeld A, Durham PL, Feoktistov A, Hay DL, Russo AF, Turner I. Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor. Neurol Ther 2021. [PMID: 34076848 DOI: 10.1007/s40120-021-00250-7] [Reference Citation Analysis]
3 Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Review of Neurotherapeutics 2019;19:769-76. [DOI: 10.1080/14737175.2019.1621749] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
4 Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14:1289-1303. [PMID: 23958278 DOI: 10.1016/j.jpain.2013.03.010] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 13.9] [Reference Citation Analysis]
5 Chan C, Goadsby PJ. Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs 2019;33:1053-71. [DOI: 10.1007/s40263-019-00665-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
6 Qin ZL, Yang LQ, Li N, Yue JN, Wu BS, Tang YZ, Guo YN, Lai GH, Ni JX. Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia. Clin Neurol Neurosurg 2016;143:111-5. [PMID: 26918582 DOI: 10.1016/j.clineuro.2016.02.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
7 Labruijere S, Stolk L, Verbiest M, de Vries R, Garrelds IM, Eilers PH, Danser AH, Uitterlinden AG, MaassenVanDenBrink A. Methylation of migraine-related genes in different tissues of the rat. PLoS One 2014;9:e87616. [PMID: 24609082 DOI: 10.1371/journal.pone.0087616] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
8 Shi M, Guo J, Li Z, Sun H, Yang X, Yang D, Zhao H. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine. Neurol Res 2021;:1-18. [PMID: 34281473 DOI: 10.1080/01616412.2021.1940672] [Reference Citation Analysis]
9 Fiedler-Kelly JB, Cohen-Barak O, Morris DN, Ludwig E, Rasamoelisolo M, Shen H, Levi M. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br J Clin Pharmacol 2019;85:2721-33. [PMID: 31418911 DOI: 10.1111/bcp.14096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
10 Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J; ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014;13:1100-7. [PMID: 25297013 DOI: 10.1016/S1474-4422(14)70209-1] [Cited by in Crossref: 247] [Cited by in F6Publishing: 108] [Article Influence: 30.9] [Reference Citation Analysis]
11 Moreno‐ajona D, Chan C, Villar‐martínez MD, Goadsby PJ. Targeting CGRP and 5‐HT 1F Receptors for the Acute Therapy of Migraine: A Literature Review. Headache: The Journal of Head and Face Pain 2019;59:3-19. [DOI: 10.1111/head.13582] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
12 Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache 2019;59:659-81. [PMID: 30982963 DOI: 10.1111/head.13529] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 23.7] [Reference Citation Analysis]
13 Will C, Messlinger K, Fischer MJ. Vessel diameter measurements at the medullary brainstem in vivo as an index of trigeminal activity. Brain Research 2016;1632:51-7. [DOI: 10.1016/j.brainres.2015.12.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Taylor FR. CGRP, Amylin, Immunology, and Headache Medicine: Headache. Headache: The Journal of Head and Face Pain 2019;59:131-50. [DOI: 10.1111/head.13432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
15 Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia 2014;34:483-92. [PMID: 24366980 DOI: 10.1177/0333102413517775] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
16 Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1091-100. [PMID: 26432181 DOI: 10.1016/S1474-4422(15)00245-8] [Cited by in Crossref: 166] [Cited by in F6Publishing: 80] [Article Influence: 23.7] [Reference Citation Analysis]
17 Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs 2014;6:871-8. [PMID: 24866108 DOI: 10.4161/mabs.29242] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
18 Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Curr Treat Options Neurol 2017;19:27. [PMID: 28653227 DOI: 10.1007/s11940-017-0463-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 15.6] [Reference Citation Analysis]
19 Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 2017;158:543-59. [PMID: 28301400 DOI: 10.1097/j.pain.0000000000000831] [Cited by in Crossref: 185] [Cited by in F6Publishing: 163] [Article Influence: 37.0] [Reference Citation Analysis]
20 Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache 2018;58 Suppl 1:33-47. [PMID: 29697153 DOI: 10.1111/head.13305] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 13.3] [Reference Citation Analysis]
21 Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A; European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18:96. [PMID: 28948500 DOI: 10.1186/s10194-017-0807-1] [Cited by in Crossref: 124] [Cited by in F6Publishing: 88] [Article Influence: 24.8] [Reference Citation Analysis]
22 Elliott MB, Oshinsky ML, Amenta PS, Awe OO, Jallo JI. Nociceptive neuropeptide increases and periorbital allodynia in a model of traumatic brain injury. Headache 2012;52:966-84. [PMID: 22568499 DOI: 10.1111/j.1526-4610.2012.02160.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
23 Bullock CM, Kelly S. Calcitonin gene-related peptide receptor antagonists: beyond migraine pain--a possible analgesic strategy for osteoarthritis? Curr Pain Headache Rep 2013;17:375. [PMID: 24068339 DOI: 10.1007/s11916-013-0375-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
24 Greco R, Mangione A, Siani F, Blandini F, Vairetti M, Nappi G, Sandrini G, Buzzi M, Tassorelli C. Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia 2014;34:594-604. [DOI: 10.1177/0333102413517776] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
25 Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F, Strassman AM, Burstein R. Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 2020;40:229-40. [PMID: 31856583 DOI: 10.1177/0333102419896760] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
26 Hargreaves R, Olesen J. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class. Headache 2019;59:951-70. [PMID: 31020659 DOI: 10.1111/head.13510] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 14.7] [Reference Citation Analysis]
27 Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol 2018;14:338-50. [DOI: 10.1038/s41582-018-0003-1] [Cited by in Crossref: 290] [Cited by in F6Publishing: 251] [Article Influence: 72.5] [Reference Citation Analysis]
28 Sohn I, Sheykhzade M, Edvinsson L, Sams A. The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas. Eur J Pharmacol 2020;881:173205. [PMID: 32442540 DOI: 10.1016/j.ejphar.2020.173205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hendrikse ER, Bower RL, Hay DL, Walker CS. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia 2019;39:403-19. [PMID: 29566540 DOI: 10.1177/0333102418765787] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
30 Wang M, Mason BN, Sowers LP, Kuburas A, Rea BJ, Russo AF. Investigating Migraine-Like Behavior using Light Aversion in Mice. J Vis Exp 2021. [PMID: 34459825 DOI: 10.3791/62839] [Reference Citation Analysis]
31 Eftekhari S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 2011;12:112. [PMID: 22074408 DOI: 10.1186/1471-2202-12-112] [Cited by in Crossref: 100] [Cited by in F6Publishing: 96] [Article Influence: 9.1] [Reference Citation Analysis]
32 Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015;15:25. [PMID: 25790955 DOI: 10.1007/s11910-015-0547-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
33 Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 2017;97:553-622. [PMID: 28179394 DOI: 10.1152/physrev.00034.2015] [Cited by in Crossref: 570] [Cited by in F6Publishing: 485] [Article Influence: 114.0] [Reference Citation Analysis]
34 Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, Yoon E, Gandhi MD, Spiegelstein O, Aycardi E. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 2018;38:1960-71. [PMID: 29667896 DOI: 10.1177/0333102418771376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
35 Johansson SE, Abdolalizadeh B, Sheykhzade M, Edvinsson L, Sams A. Vascular pathology of large cerebral arteries in experimental subarachnoid hemorrhage: Vasoconstriction, functional CGRP depletion and maintained CGRP sensitivity. Eur J Pharmacol 2019;846:109-18. [PMID: 30653947 DOI: 10.1016/j.ejphar.2019.01.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
36 Cheng CK, Bakar HA, Gollasch M, Huang Y. Perivascular Adipose Tissue: the Sixth Man of the Cardiovascular System. Cardiovasc Drugs Ther 2018;32:481-502. [PMID: 30171461 DOI: 10.1007/s10557-018-6820-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
37 Raddant AC, Russo AF. Reactive oxygen species induce procalcitonin expression in trigeminal ganglia glia. Headache 2014;54:472-84. [PMID: 24512072 DOI: 10.1111/head.12301] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
38 Shah KA, White TG, Powell K, Woo HH, Narayan RK, Li C. Trigeminal Nerve Stimulation Improves Cerebral Macrocirculation and Microcirculation After Subarachnoid Hemorrhage: An Exploratory Study. Neurosurgery 2022. [PMID: 35188109 DOI: 10.1227/NEU.0000000000001854] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep 2015;19:6. [PMID: 25754596 DOI: 10.1007/s11916-015-0476-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
40 Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci 2012;19:88-94. [PMID: 25205974 DOI: 10.5214/ans.0972.7531.12190210] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
41 Warfvinge K, Edvinsson L. Pearls and pitfalls in neural CGRP immunohistochemistry. Cephalalgia 2013;33:593-603. [DOI: 10.1177/0333102412472072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
42 Labruijere S, van Houten EL, de Vries R, Musterd-Bagghoe UM, Garrelds IM, Kramer P, Danser AH, Villalón CM, Visser JA, Van Den Brink AM. Analysis of the vascular responses in a murine model of polycystic ovary syndrome. J Endocrinol 2013;218:205-13. [PMID: 23734045 DOI: 10.1530/JOE-13-0094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
43 Cowie AM, Moehring F, O'Hara C, Stucky CL. Optogenetic Inhibition of CGRPα Sensory Neurons Reveals Their Distinct Roles in Neuropathic and Incisional Pain. J Neurosci 2018;38:5807-25. [PMID: 29925650 DOI: 10.1523/JNEUROSCI.3565-17.2018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 10.7] [Reference Citation Analysis]
44 Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. Expert Opinion on Drug Discovery 2013;8:1309-23. [DOI: 10.1517/17460441.2013.826644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Bigal ME, Walter S, Rapoport AM. The vasodilatory activity of CGRP: a response. Headache 2014;54:748-9. [PMID: 24697226 DOI: 10.1111/head.12316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Michot B, Kayser V, Hamon M, Bourgoin S. CGRP receptor blockade by MK-8825 alleviates allodynia in infraorbital nerve-ligated rats. Eur J Pain 2015;19:281-90. [PMID: 25370954 DOI: 10.1002/ejp.616] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
47 Eftekhari S, Salvatore CA, Johansson S, Chen T, Zeng Z, Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier. Brain Research 2015;1600:93-109. [DOI: 10.1016/j.brainres.2014.11.031] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 19.3] [Reference Citation Analysis]
48 Hoffmann J, Wecker S, Neeb L, Dirnagl U, Reuter U. Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. Cephalalgia 2012;32:659-67. [DOI: 10.1177/0333102412447701] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
49 Sari Aslani P, Hassanpour M, Razi O, Knechtle B, Parnow A. Resistance training reduces pain indices and improves quality of life and body strength in women with migraine disorders. Sport Sci Health. [DOI: 10.1007/s11332-021-00822-y] [Reference Citation Analysis]
50 Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1081-90. [PMID: 26432182 DOI: 10.1016/S1474-4422(15)00249-5] [Cited by in Crossref: 184] [Cited by in F6Publishing: 77] [Article Influence: 26.3] [Reference Citation Analysis]
51 Hoehlig K, Johnson KW, Pryazhnikov E, Maasch C, Clemens-Smith A, Purschke WG, Vauléon S, Buchner K, Jarosch F, Khiroug L, Vater A, Klussmann S. A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation. Br J Pharmacol 2015;172:3086-98. [PMID: 25659966 DOI: 10.1111/bph.13110] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
52 Hoffmann J, Goadsby PJ. New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr Treat Options Neurol 2012;14:50-9. [PMID: 22090312 DOI: 10.1007/s11940-011-0155-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
53 Benemei S, Fusi C, Trevisan G, Geppetti P. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014;171:2552-67. [PMID: 24206166 DOI: 10.1111/bph.12512] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 10.6] [Reference Citation Analysis]
54 He J, Bazan HE. Morphology and neurochemistry of rabbit iris innervation. Exp Eye Res 2015;135:182-91. [PMID: 25752697 DOI: 10.1016/j.exer.2015.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Andreou AP, Fuccaro M, Lambru G. The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord 2020;13:1756286420927119. [PMID: 32523630 DOI: 10.1177/1756286420927119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Parikh SK, Silberstein SD. Preventive Treatment for Episodic Migraine. Neurol Clin 2019;37:753-70. [PMID: 31563231 DOI: 10.1016/j.ncl.2019.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
57 Asghar MS, Hansen AE, Larsson HB, Olesen J, Ashina M. Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain 2012;13:159-66. [PMID: 22246026 DOI: 10.1007/s10194-011-0415-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
58 Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab 2019;39:573-94. [PMID: 28948863 DOI: 10.1177/0271678X17733655] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
59 Bigal ME, Walter S, Rapoport AM. Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development. Headache: The Journal of Head and Face Pain 2013;53:1230-44. [DOI: 10.1111/head.12179] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 10.2] [Reference Citation Analysis]
60 Michot B, Bourgoin S, Viguier F, Hamon M, Kayser V. Differential effects of calcitonin gene-related peptide receptor blockade by olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain 2012;153:1939-48. [PMID: 22795918 DOI: 10.1016/j.pain.2012.06.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
61 Jones A, Cohen-Barak O, Radivojevic A, Fiedler-Kelly J. Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study. Pharmaceutics 2021;13:785. [PMID: 34074002 DOI: 10.3390/pharmaceutics13060785] [Reference Citation Analysis]
62 Matsuka Y, Afroz S, Dalanon JC, Iwasa T, Waskitho A, Oshima M. The role of chemical transmitters in neuron-glia interaction and pain in sensory ganglion. Neuroscience & Biobehavioral Reviews 2020;108:393-9. [DOI: 10.1016/j.neubiorev.2019.11.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
63 Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother 2013;14:1599-610. [PMID: 23815106 DOI: 10.1517/14656566.2013.806487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
64 Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C, Edvinsson L. Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience 2016;328:165-83. [PMID: 27155150 DOI: 10.1016/j.neuroscience.2016.04.046] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
65 Bigal ME. BMS-927711 for the acute treatment of migraine. Cephalalgia 2014;34:90-2. [DOI: 10.1177/0333102413500728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
66 Grell A, Haanes KA, Johansson SE, Edvinsson L, Sams A. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. European Journal of Pharmacology 2019;864:172726. [DOI: 10.1016/j.ejphar.2019.172726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014;28:389-99. [PMID: 24638916 DOI: 10.1007/s40263-014-0156-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]